Mangalam Drugs & Organics Limited has issued a notice seeking shareholder approval through a postal ballot for the re-appointment of Shri Praveen Saxena as an Independent Director. The resolution proposes a second term of five consecutive years commencing from March 21, 2026, to March 20, 2031. The notice has been dispatched pursuant to the provisions of the Companies Act, 2013, and SEBI Listing Regulations.

Postal Ballot and E-Voting Timeline

The company has established the following schedule for the remote e-voting process:

Shareholders whose names appear in the Register of Members or List of Beneficial Owners as on the cut-off date are entitled to cast their votes. The company has engaged National Securities Depository Limited (NSDL) to provide the remote e-voting facility.

Scrutinizer Appointment

The Board of Directors has appointed Shri Brij Mohan Maheshwari, Advocate Proprietor of M/s. B.M.M & Associates, Indore, as the Scrutinizer. He will oversee the postal ballot and e-voting process to ensure it is conducted in a fair and transparent manner. The results of the postal ballot will be submitted to the stock exchanges within 48 hours from the conclusion of the e-voting period.

Director Profile

Shri Praveen Saxena (DIN: 03199264) is an international expert with extensive experience in energy policy and renewable energy programs. He holds a Ph.D. in Physics and was conferred with the International Business Leadership Innovation Excellence Award in 2017. His first term as Independent Director expired on March 20, 2026. The Nomination and Remuneration Committee and the Board of Directors have recommended his re-appointment based on his performance and expertise.

Mangalam Drugs and Organics Limited reported a sharp reversal in financial performance for the quarter and fiscal year ended March 31, 2026, swinging to a consolidated net loss of ₹4,440.00 lakh from a net profit of ₹672.07 lakh in the previous year. The Board of Directors approved both the standalone and consolidated audited financial results at their meeting held on May 14, 2026. Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audited financial results were subsequently published in Financial Express and Loksatta newspapers, with the advertisement copies submitted to the stock exchanges on May 15, 2026 by Chairman and Managing Director Govardhan M. Dhoot. The results were prepared in accordance with Indian Accounting Standards (Ind AS) under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors V.S. Somani & Co., Chartered Accountants, issued an unmodified audit opinion on both the standalone and consolidated financial results.

Consolidated Annual Financial Performance

On a consolidated basis, revenue from operations for the year declined significantly to ₹23,213.27 lakh from ₹31,757.60 lakh in the prior year. Total income stood at ₹23,289.58 lakh against ₹31,873.28 lakh previously. Total expenses for the year were ₹28,146.72 lakh compared to ₹31,394.70 lakh in the prior year. The consolidated loss before tax for the year was ₹4,857.14 lakh against a profit before tax of ₹478.58 lakh in the previous year. After a net tax credit of ₹417.13 lakh, the net loss stood at ₹4,440.00 lakh. Total comprehensive loss for the year was ₹4,485.24 lakh. The basic and diluted earnings per share (EPS) for the year were reported at a loss of ₹28.05, compared to an EPS of ₹4.25 in the previous year.

The following table summarises the key consolidated annual financial results:

Quarterly Consolidated Results

For the quarter ended March 31, 2026, the company reported a consolidated net loss of ₹1,342.00 lakh, compared to a net profit of ₹5.94 lakh in the corresponding quarter of the previous year. Revenue from operations for the quarter was ₹6,728.71 lakh, while total income stood at ₹6,737.65 lakh. Total expenses for the quarter amounted to ₹8,064.79 lakh. The basic and diluted EPS for the quarter was a loss of ₹8.48.

Standalone Financial Performance

On a standalone basis, the company reported a net loss of ₹4,381.42 lakh for the year ended March 31, 2026, compared to a net profit of ₹692.43 lakh in the previous year. Standalone revenue from operations was ₹23,213.27 lakh against ₹31,757.60 lakh previously. Total standalone expenses for the year were ₹28,088.32 lakh. The standalone basic and diluted EPS for the year was a loss of ₹27.68, compared to a profit of ₹4.37 in the prior year. Total comprehensive loss on a standalone basis was ₹4,426.66 lakh. For the quarter ended March 31, 2026, the standalone net loss was ₹1,306.04 lakh, with basic and diluted EPS of ₹(8.25), compared to a net profit of ₹15.09 lakh in the corresponding quarter of the previous year.

Standalone Quarterly Results

Consolidated Balance Sheet Highlights

The consolidated balance sheet as at March 31, 2026 reflects total assets of ₹31,496.93 lakh, down from ₹36,642.17 lakh as at March 31, 2025. Total equity stood at ₹10,305.90 lakh compared to ₹14,897.90 lakh in the prior year, reflecting the impact of the net loss for the year. Current borrowings rose to ₹9,455.80 lakh from ₹7,095.51 lakh, while inventories declined to ₹10,277.36 lakh from ₹13,880.18 lakh. Consolidated cash and cash equivalents at the close of the year stood at ₹70.10 lakh, down from ₹258.89 lakh at the start of the year.

Operational and Corporate Updates

The group's business activity falls within a single reportable segment: "Manufacturing of Bulk Drugs." The consolidated results include the financials of Mangalam Laboratories Private Limited (MLPL), a wholly-owned subsidiary, which is not classified as a material subsidiary. The subsidiary reported total assets (before consolidation adjustments) of ₹687.51 lakh, total revenue (before consolidation adjustments) of ₹30.45 lakh, and a total net loss after tax (before consolidation adjustments) of ₹58.58 lakh for the year. The Board had previously approved a scheme of merger by absorption of Mangalam Laboratories Private Limited and Shri JB Pharma Private Limited with the company, subject to approval of the National Company Law Tribunal, with the hearing scheduled for June 2, 2026. The company also noted that the Government of India notified four Labour Codes consolidating 29 existing labour laws, and based on management assessment, the incremental impact of these changes is not material to the financial results for the year.